Related references
Note: Only part of the references are listed.Trastuzumab Treatment in T1ab, Node-Negative, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Carcinomas
Manuel Jorge Rodrigues et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
Giuseppe Curigliano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller
Ana M. Gonzalez-Angulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M. Untch et al.
ANNALS OF ONCOLOGY (2008)
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)